Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Esperion (ESPR).
Esperion Therapeutics, Inc. has announced the departure of their Chief Medical Officer, Dr. JoAnne Foody, with a planned separation by September 16, 2024. Dr. Foody will transition to a Senior Advisor role and continue to earn her current salary until the separation date. Post-departure, she will receive a severance package including a year’s salary paid over 12 months, health insurance contributions, a prorated 2024 bonus, and an extension on exercising her vested stock options. Dr. Foody will also uphold her non-compete and confidentiality obligations and has provided a general release of claims to the company.
Learn more about ESPR stock on TipRanks’ Stock Analysis page.
